Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19226034 | 0.92 | ABL1 (0.69) | ABL1 | |
| SCHEMBL15391645 | 0.88 | ABL1 (0.71) | ABL1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL15388266 | 0.86 | ABL1 (0.68) | ABL1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL15391654 | 0.86 | ABL1 (0.68) | ABL1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL15388382 | 0.86 | ABL1 (0.69) | ABL1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL15391649 | 0.85 | ABL1 (0.61) | ABL1MEN1KMT2A | |
| SCHEMBL15391683 | 0.83 | ABL1 (0.64) | ABL1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL15391366 | 0.81 | ABL1 (1.00) | ABL1 | |
| SCHEMBL19226013 | 0.80 | TRPV1 (0.68) | ABL1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL16714121 | 0.79 | ABL1 (1.00) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-05-17 | — | — | US | disclosed |
| EP-2861579-B1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-21 | — | — | EP | disclosed |
| US-9896444-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| EP-2900637-B1 | THIAZOLE OR IMIDAZOLE SUBSTITUTED PYRIMIDINE, PYRIDINE AND PYRAZINE AMIDE DERIVATIVES AND RELATED COMPOUNDS AS ABL1, ABL2 AND BCR-ABL1 INHIBITORS FOR THE TREATMENT OF CANCER, SPECIFIC VIRAL INFECTIONS AND SPECIFIC CNS DISORDERS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ABL1 1/4885MEN1 2110/4885KMT2A 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.